Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

MDM2 amplification

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

MDM2 amplification	Hormone Receptor Positive Breast Cancer	MDM2 amplification	Hormone Receptor Positive Breast Cancer	RAIN-32 Sensitive: D – Preclinical SABCS 2022 - 6 days (New D) RAIN-32 Sensitive : D SABCS 2022 - 6d	RAIN-32 Sensitive: D – Preclinical SABCS 2022 - 6 days RAIN-32 Sensitive : D SABCS 2022 - 6 days - (New D)
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2	APG-115 Sensitive: C2 – Inclusion Criteria APG-115 Sensitive : C2
MDM2 amplification	Solid Tumor	MDM2 amplification	Solid Tumor	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2	RAIN-32 Sensitive: C2 – Inclusion Criteria RAIN-32 Sensitive : C2
MDM2 amplification	Liposarcoma	MDM2 amplification	Liposarcoma	BI 907828 Sensitive: C2 – Inclusion Criteria BI 907828 Sensitive : C2	BI 907828 Sensitive: C2 – Inclusion Criteria BI 907828 Sensitive : C2
MDM2 amplification	Solid Tumor	MDM2 amplification	Solid Tumor	BI 907828 Sensitive: C2 – Inclusion Criteria BI 907828 Sensitive : C2	BI 907828 Sensitive: C2 – Inclusion Criteria BI 907828 Sensitive : C2
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3	ipilimumab Resistant: C3 – Early Trials ipilimumab Resistant : C3
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3	nivolumab + ipilimumab Resistant: C3 – Early Trials nivolumab + ipilimumab Resistant : C3
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3	nivolumab Resistant: C3 – Early Trials nivolumab Resistant : C3
MDM2 amplification	Mucosal Melanoma	MDM2 amplification	Mucosal Melanoma	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3	pembrolizumab Resistant: C3 – Early Trials pembrolizumab Resistant : C3
MDM2 amplification	Gastric Adenocarcinoma	MDM2 amplification	Gastric Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
MDM2 amplification	Sarcoma	MDM2 amplification	Sarcoma	RAIN-32 Sensitive: C3 – Early Trials RAIN-32 Sensitive : C3	RAIN-32 Sensitive: C3 – Early Trials RAIN-32 Sensitive : C3
MDM2 amplification	Diffuse Large B Cell Lymphoma	MDM2 amplification	Diffuse Large B Cell Lymphoma	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3	R-CHOP Resistant: C3 – Early Trials R-CHOP Resistant : C3
MDM2 amplification	Solid Tumor	MDM2 amplification	Solid Tumor	BI 907828 + BI 754091 Sensitive: C3 – Early Trials BI 907828 + BI 754091 Sensitive : C3	BI 907828 + BI 754091 Sensitive: C3 – Early Trials BI 907828 + BI 754091 Sensitive : C3
MDM2 amplification	Triple Negative Breast Cancer	MDM2 amplification	Triple Negative Breast Cancer	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4	pembrolizumab Resistant: C4 – Case Studies pembrolizumab Resistant : C4